共 50 条
- [1] Daratumumab plus Bortezomib-Melphalan-Prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE)ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 182 - 182Cavo, M.Iida, S.Blade, J.Mateos, M-, VLee, J-JGarg, M.Hungria, VBeksac, M.Spicka, IKnop, S.Pour, L.Campbell, P.Jakubowiak, A.Wang, J.Wroblewski, S.Kobos, R.Qi, M.San-Miguel, J.
- [2] Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE)ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 182 - 183Cavo, M.Dimopoulos, M. A.San-Miguel, J.Jakubowiak, A.Suzuki, K.Yoon, S-SCook, M.Boccadoro, M.Ho, P. J.Pour, L.Knop, S.Doyen, C.Crepaldi, A.Masszi, T.Blade, J.Wang, J.Wroblewski, S.Deraedt, W.Qi, M.Mateos, M-, V
- [3] Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Cavo, MicheleDimopoulos, Meletios A.San-Miguel, JesusJakubowiak, Andrzej J.Suzuki, KenshiYoon, Sung-SooCook, MarkBoccadoro, MarioHo, P. JoyPour, LudekKnop, StefanDoyen, ChantalMasszi, TamasBlade, JoanWang, JianpingWroblewski, SusanDeraedt, WilliamQi, MingMateos, Maria-Victoria
- [4] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)HAEMATOLOGICA, 2018, 103 : 22 - 22Mateos, M., VDimopoulos, M. A.Cavo, M.Suzuki, K.Jakubowiak, A.Knop, S.Doyen, C.Lucio, P.Nagy, Z.Kaplan, P.PouCook, M.Grosicki, S.Crepaldi, A.Liberati, A. M.Campbell, P.Shelekhova, T.Yoon, S. S.Iosava, G.Fujisaki, T.Garg, M.Chiu, C.Wang, J.Carson, R.Crist, W.Deraedt, W.Nguyen, H.Qi, M.San-Miguel, J.
- [5] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)BLOOD, 2017, 130Mateos, Maria-VictoriaDimopoulos, Meletios A.Cavo, MicheleSuzuki, KenshiJakubowiak, Andrzej J.Knop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltKaplan, PolinaPour, LudekCook, MarkGrosicki, SebastianCrepaldi, Andre H.Liberati, Anna MarinaCampbell, PhilipShelekhova, TatianaYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaChiu, ChristopherWang, JianpingCarson, RobinCrist, WendyDeraedt, WilliamNguyen, MarieQi, MingSan-Miguel, Jesus F.
- [6] Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone StudyBLOOD, 2022, 140 : 10157 - 10159Mateos, Maria-VictoriaSan-Miguel, JesusCavo, MicheleCreixenti, Joan BladeSuzuki, KenshiJakubowiak, AndrzejKnop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltPour, LudekGrosicki, SebastianCrepaldi, Andre H.Liberati, Anna MarinaCampbell, PhilipShelekhova, TatianaYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaPei, HuilingKrevvata, MariaCarson, RobinBorgsten, FredrikDimopoulos, Meletios A.
- [7] One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): AlcyoneBLOOD, 2018, 132Dimopoulos, Meletios A.Mateos, Maria-VictoriaCavo, MicheleSuzuki, KenshiJakubowiak, AndrzejKnop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltKaplan, PolinaPour, LudekCook, MarkGrosicki, SebastianCrepaldi, Andre H.Liberati, Anna MarinaCampbell, PhilipShelekhova, TatianaYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaChiu, ChristopherWang, JianpingKudva, AnupaKobos, RachelWroblewski, SusanQi, MingSan-Miguel, Jesus F.Blade, Joan
- [8] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in AlcyoneBLOOD, 2019, 134Mateos, Maria-VictoriaCavo, MicheleBlade, JoanDimopoulos, Meletios A.Suzuki, KenshiJakubowiak, AndrzejKnop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltPour, LudekCook, MarkGrosicki, SebastianCrepaldi, Andre H.Liberati, Anna MarinaCampbell, PhilipShelekhova, TatianaYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaKrevvata, MariaWang, JianpingKudva, AnupaUkropec, JonWroblewski, SusanKobos, RachelSan-Miguel, Jesus
- [9] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONECLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798Mateos, Maria-VictoriaDimopoulos, Meletios A.Cavo, MicheleSuzuki, KenshiKnop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltPour, LudekGrosicki, SebastianCrepaldi, AndreLiberati, Anna MarinaCampbell, PhilipYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaIida, ShinsukeBlade, JoanUkropec, JonPei, HuilingVan Rampelbergh, RianKudva, AnupaQi, MingSan-Miguel, Jesus
- [10] Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)BLOOD, 2018, 132Cavo, MicheleDimopoulos, Meletios A.San-Miguel, Jesus F.Mateos, Maria-VictoriaJakubowiak, AndrzejDeraedt, WilliamLam, AnnetteKampfenkel, TobiasQi, MingHe, Jianming